Hot Pursuit     08-Mar-23
Alembic Pharma gets USFDA final approval for Prazosin Hydrochloride capsules
The drug maker announced that it has received final approval from US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Prazosin Hydrochloride capsules.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Minipress capsules of Pfizer Inc. Prazosin Hydrochloride capsule is indicated for the treatment of hypertension, to lower blood pressure.

Prazosin Hydrochloride capsules has an estimated market size of $50 million for twelve months ending December 2022 according to IQVIA.

Alembic has a cumulative total of 183 ANDA approvals (160 final approvals and 23 tentative approvals) from USFDA.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. The company manufactures and markets generic pharmaceutical products all over the world.

The drug maker reported 29% drop in consolidated net profit to Rs 121.92 crore despite a 18.7% rise in net sales to Rs 1,509.02 crore in Q3 FY23 over Q3 FY22.

The scrip was down 0.88% to Rs 521 on the BSE.

Previous News
  Alembic Pharmaceuticals consolidated net profit rises 596.17% in the March 2023 quarter
 ( Results - Announcements 05-May-23   17:32 )
  Alembic Pharmaceuticals consolidated net profit rises 16.78% in the March 2024 quarter
 ( Results - Announcements 09-May-24   15:06 )
  Alembic Pharmaceuticals receives USFDA tentative approval for Ivosidenib Tablets
 ( Corporate News - 04-Jul-24   16:11 )
  Board of Alembic Pharmaceuticals recommends Final Dividend
 ( Corporate News - 05-May-23   17:26 )
  Board of Alembic Pharmaceuticals recommends final dividend
 ( Corporate News - 06-May-23   09:20 )
  Alembic Pharmaceuticals Ltd gains for third straight session
 ( Hot Pursuit - 13-May-22   13:05 )
  CRISIL reaffirms ratings of Alembic Pharmaceuticals with 'stable' outlook
 ( Hot Pursuit - 08-Mar-24   11:22 )
  Alembic Pharmaceuticals receives USFDA tentative approval for Ribociclib Tablets
 ( Corporate News - 01-Apr-24   11:51 )
  Alembic Pharma rises after receiving tentative approval for anti anginal drug
 ( Hot Pursuit - 20-Apr-22   11:30 )
  Alembic Pharma Q3 PAT slips 29% YoY; R&D spend at Rs 157 crore
 ( Hot Pursuit - 02-Feb-23   10:41 )
  Alembic Pharmaceuticals rises after receiving USFDA nod for pulmonary fibrosis drug
 ( Hot Pursuit - 24-May-22   11:12 )
Other Stories
  Marine Electricals jumps after order win
  08-Jul-24   14:33
  Volumes soar at Metro Brands Ltd counter
  08-Jul-24   14:30
  Metal stocks edge lower
  08-Jul-24   14:01
  Basic materials shares fall
  08-Jul-24   14:01
  Consumer Durables stocks slide
  08-Jul-24   14:00
  Central Bank of India eases for fifth straight session
  08-Jul-24   13:36
  Apollo Tyres Ltd eases for fifth straight session
  08-Jul-24   13:35
  Reliance Industries Ltd up for third straight session
  08-Jul-24   13:06
  Oil & Natural Gas Corpn Ltd rises for third consecutive session
  08-Jul-24   13:05
  Zydus Lifesciences Ltd spurts 0.43%, up for five straight sessions
  08-Jul-24   13:01
Back Top